Clinical observation of nedaplatin in the treatment of advanced non-small cell lung cancer

Objective:To observe the efficacy and side effects of gemcitabine combined with nedaplatin and cisplatin in the treatment of advanced non-smal cell lung cancer(NSCLC).Methods:A total of 60 patients with advanced non-small cell lung cancer were divided into the gemcitabine combined with nedaplatin group(group GN,n=30): Gemcitabine 1 000mg/m2,d1,8,iv drip;nedaplatin 80mg/m2,d2,iv drip;And the gemcitabine combined with cisplatin group(group GP,n=30).Gemcitabine 1 000mg/m2,d1,8,iv drip;cisplatin80-100 mg/ m2,divided into three days to iv drip.All patients were undergone 2 cycles,each cycle 21 days.Results: The efficacy of group GN was 36.67% and group GP was 40.00%,there was no significant difference between the two group in curative effect(P0.05).A higher response rate of digestive reaction(80.0%) occurred in group GP,compared to that occurred in group GP(56.7%),with a significant difference between the two groups(P0.05).There was no significant difference between two groups in the toxicity of kidney.There was a lower incidence of leucopenia response rate(50.0%) in group GP than in group GN(56.7%),but no significant difference between the groups(P0.05).There was a lower thrombocytopenia response rate(66.7%) in group GP than in group GN(73.3%),but no significant difference between the groups(P0.05).Conclusion:There is no significant difference between gemcitabine combined with cisplatin group and nedaplain group in the effect and there is a lower digestive reaction than cisplatin group.the main adverse reaction was myelosuppression and allergic reaction,in the treatment of NSCLC.